Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer.

Literature DB >> 15173101

Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer.

Gordon J S Rustin¹, Robert C Bast, Gary J Kelloff, J Carl Barrett, Stephen K Carter, Perry D Nisen, Caroline C Sigman, David R Parkinson, Raymond W Ruddon.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2004 PMID： 15173101 DOI： 10.1158/1078-0432.CCR-03-0787

Source DB: PubMed Journal: Clin Cancer Res ISSN： 1078-0432 Impact factor: 12.531

Keyword Cloud
Cited

× No keyword cloud information.

41 in total

1. Novel monoclonal antibodies against the proximal (carboxy-terminal) portions of MUC16.

Authors: Thapi Dharma Rao; Kay J Park; Peter Smith-Jones; Alexia Iasonos; Irina Linkov; Robert A Soslow; David R Spriggs
Journal: Appl Immunohistochem Mol Morphol Date: 2010-10

2. Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: a 2-cohort, phase 2 study.

Authors: Martee L Hensley; Sara Kravetz; Xiaoyu Jia; Alexia Iasonos; William Tew; Lauren Pereira; Paul Sabbatini; Christin Whalen; Carol A Aghajanian; Corinne Zarwan; Suzanne Berlin
Journal: Cancer Date: 2011-09-20 Impact factor: 6.860

Review 3. Translational research in phase I trials.

Authors: Angelica Fasolo; Cristiana Sessa
Journal: Clin Transl Oncol Date: 2009-09 Impact factor: 3.405

4. A phase 2 study of oxaliplatin combined with continuous infusion topotecan for patients with previously treated ovarian cancer.

Authors: Stacey M Stein; Amy Tiersten; Howard S Hochster; Stephanie V Blank; Bhavana Pothuri; John Curtin; Ilan Shapira; Benjamin Levinson; Percy Ivy; Benson Joseph; Achuta Kumar Guddati; Franco Muggia
Journal: Int J Gynecol Cancer Date: 2013-11 Impact factor: 3.437

Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer.

1. Novel monoclonal antibodies against the proximal (carboxy-terminal) portions of MUC16.

2. Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: a 2-cohort, phase 2 study.

Review 3. Translational research in phase I trials.

4. A phase 2 study of oxaliplatin combined with continuous infusion topotecan for patients with previously treated ovarian cancer.

Review 5. New technologies in cancer. Protein microarrays for biomarker discovery.

6. The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass.

7. TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients.

8. Pegylated liposomal doxorubicin in ovarian cancer.

9. Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature.

10. Mucins in ovarian cancer diagnosis and therapy.